vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and GCL Global Holdings Ltd (GCL). Click either name above to swap in a different company.

GCL Global Holdings Ltd is the larger business by last-quarter revenue ($98.7M vs $85.1M, roughly 1.2× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -5.2%, a 28.0% gap on every dollar of revenue. 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-5.2M).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

GCL Global Holdings Ltd is a leading clean energy enterprise focusing on R&D, production and operation of photovoltaic products, energy storage systems and low-carbon energy solutions. Its main markets cover Asia, Europe, North America, serving utility, commercial and residential distributed energy users across the globe.

FDMT vs GCL — Head-to-Head

Bigger by revenue
GCL
GCL
1.2× larger
GCL
$98.7M
$85.1M
FDMT
Higher net margin
FDMT
FDMT
28.0% more per $
FDMT
22.8%
-5.2%
GCL
More free cash flow
FDMT
FDMT
$33.7M more FCF
FDMT
$28.5M
$-5.2M
GCL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FDMT
FDMT
GCL
GCL
Revenue
$85.1M
$98.7M
Net Profit
$19.4M
$-5.1M
Gross Margin
11.0%
Operating Margin
17.3%
-6.7%
Net Margin
22.8%
-5.2%
Revenue YoY
8508900.0%
Net Profit YoY
139.1%
EPS (diluted)
$0.43
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
GCL
GCL
Q4 25
$85.1M
Q3 25
$90.0K
$98.7M
Q2 25
$15.0K
$142.1M
Q1 25
$14.0K
Q4 24
$1.0K
Q3 24
$3.0K
$36.1M
Q2 24
$5.0K
Q1 24
$28.0K
Net Profit
FDMT
FDMT
GCL
GCL
Q4 25
$19.4M
Q3 25
$-56.9M
$-5.1M
Q2 25
$-54.7M
$5.6M
Q1 25
$-48.0M
Q4 24
Q3 24
$-43.8M
$-1.9M
Q2 24
$-35.0M
Q1 24
$-32.4M
Gross Margin
FDMT
FDMT
GCL
GCL
Q4 25
Q3 25
11.0%
Q2 25
15.0%
Q1 25
Q4 24
Q3 24
16.2%
Q2 24
Q1 24
Operating Margin
FDMT
FDMT
GCL
GCL
Q4 25
17.3%
Q3 25
-67983.3%
-6.7%
Q2 25
-396373.3%
2.3%
Q1 25
-383007.1%
Q4 24
Q3 24
-1704400.0%
-5.6%
Q2 24
-849120.0%
Q1 24
-136200.0%
Net Margin
FDMT
FDMT
GCL
GCL
Q4 25
22.8%
Q3 25
-63195.6%
-5.2%
Q2 25
-364386.7%
3.9%
Q1 25
-342657.1%
Q4 24
Q3 24
-1461433.3%
-5.2%
Q2 24
-699060.0%
Q1 24
-115717.9%
EPS (diluted)
FDMT
FDMT
GCL
GCL
Q4 25
$0.43
Q3 25
$-1.01
$-0.04
Q2 25
$-0.98
$0.05
Q1 25
$-0.86
Q4 24
Q3 24
$-0.79
Q2 24
$-0.63
Q1 24
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
GCL
GCL
Cash + ST InvestmentsLiquidity on hand
$402.7M
$16.6M
Total DebtLower is stronger
$52.0M
Stockholders' EquityBook value
$505.7M
$33.1M
Total Assets
$566.7M
$159.9M
Debt / EquityLower = less leverage
1.57×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
GCL
GCL
Q4 25
$402.7M
Q3 25
$305.1M
$16.6M
Q2 25
$293.2M
$18.2M
Q1 25
$321.4M
Q4 24
$424.9M
Q3 24
$501.9M
$2.7M
Q2 24
$541.9M
Q1 24
$525.9M
Total Debt
FDMT
FDMT
GCL
GCL
Q4 25
Q3 25
$52.0M
Q2 25
$11.9M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
FDMT
FDMT
GCL
GCL
Q4 25
$505.7M
Q3 25
$369.0M
$33.1M
Q2 25
$420.9M
$35.9M
Q1 25
$469.7M
Q4 24
$510.6M
Q3 24
$552.9M
$15.9M
Q2 24
$588.3M
Q1 24
$600.6M
Total Assets
FDMT
FDMT
GCL
GCL
Q4 25
$566.7M
Q3 25
$424.0M
$159.9M
Q2 25
$473.6M
$101.6M
Q1 25
$515.7M
Q4 24
$560.4M
Q3 24
$604.0M
$49.6M
Q2 24
$620.1M
Q1 24
$629.9M
Debt / Equity
FDMT
FDMT
GCL
GCL
Q4 25
Q3 25
1.57×
Q2 25
0.33×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
GCL
GCL
Operating Cash FlowLast quarter
$28.6M
$-4.8M
Free Cash FlowOCF − Capex
$28.5M
$-5.2M
FCF MarginFCF / Revenue
33.5%
-5.3%
Capex IntensityCapex / Revenue
0.1%
0.4%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
GCL
GCL
Q4 25
$28.6M
Q3 25
$-46.5M
$-4.8M
Q2 25
$-43.4M
$-10.3M
Q1 25
$-47.8M
Q4 24
$-134.6M
Q3 24
$-29.4M
$6.1M
Q2 24
$-30.2M
Q1 24
$-29.1M
Free Cash Flow
FDMT
FDMT
GCL
GCL
Q4 25
$28.5M
Q3 25
$-46.6M
$-5.2M
Q2 25
$-43.4M
$-10.5M
Q1 25
$-48.4M
Q4 24
$-138.4M
Q3 24
$-31.2M
Q2 24
$-30.6M
Q1 24
$-29.8M
FCF Margin
FDMT
FDMT
GCL
GCL
Q4 25
33.5%
Q3 25
-51765.6%
-5.3%
Q2 25
-289620.0%
-7.4%
Q1 25
-345635.7%
Q4 24
-13837100.0%
Q3 24
-1038966.7%
Q2 24
-611840.0%
Q1 24
-106421.4%
Capex Intensity
FDMT
FDMT
GCL
GCL
Q4 25
0.1%
Q3 25
101.1%
0.4%
Q2 25
440.0%
0.1%
Q1 25
4507.1%
Q4 24
378600.0%
Q3 24
59266.7%
Q2 24
6980.0%
Q1 24
2535.7%
Cash Conversion
FDMT
FDMT
GCL
GCL
Q4 25
1.47×
Q3 25
Q2 25
-1.84×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons